Cambridge, Ma., USA - November 25, 2009, Cambridge, Ma., USA - Molecular Insight Pharmaceuticals, a biopharmaceutical company, announced that Anthony F. Martin would resign as a director and a member of all committees, effective December 31, and Harry Stylli would not stand for re-election at the annual meeting of shareholders in May 2010 and would resign as a director and a member of all committees.
Article continues below
Dr. Martin, Ph.D., who joined the Molecular Insight Board of Directors in September 2008, has more than 20 years' experience in providing life science and biotechnology companies counsel on a range of strategic, management and funding issues. Dr. Martin is the Founder and Managing Partner of TMA Consultants. Dr. Martin has most recently served as Non-Executive Director of Prelude Trust plc, and as Chairman of NeuTec Pharma plc, playing a pivotal role in guiding the biopharmaceutical company’s listing on the AIM market in the United Kingdom and its subsequent sale to Novartis.
Dr. Martin has also held senior positions in a number of well-known life science businesses both in the United Kingdom and United States including: Managing Director of British Biotech Products Ltd, Chairman, President and CEO of Molecular Probes, President of Molecular Biology, Invitrogen Corporation, Chairman and CEO of AZUR Environmental, CEO of Celsis International plc, as well as senior leadership roles at Amersham International plc.
Dr. Martin holds a Ph.D. in Immunology and a first class honors degree in Applied Chemistry from the Universities of Manchester and Huddersfield, UK. In addition, Dr. Martin is currently Chairman of Sphere Medical Holdings plc, Wound Solutions Ltd. and Safeguard Biosystems Holdings Ltd.
Dr. Stylli, Ph.D., has served as a member of our Board of Directors since 2004. Dr. Stylli is the former Chief Executive Officer and President of Sequenom. From 2004 until 2005 he was President and Chief Executive Officer of Xenecor. Dr. Stylli co-founded Aurora Biosciences in 1995, where he served as Senior Vice President of Screening Technology and New Ventures from 2001 to 2002 and as Senior Vice President of Commercial Development from 1999 to 2001.
In 2001, following the merger between Aurora and Vertex Pharmaceuticals, Dr. Stylli served as President of Aurora Biosciences and Panvera. From 2002 to 2003, he served as President and Chief Executive Officer of CovX Pharmaceuticals. From 1987 to 1995, Dr. Stylli held varying positions of increasing responsibility in the global discovery organization of GlaxoSmithKline. ■